PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?

Abstract Purpose. To identify pathological characteristics of prostate cancer according to patient age at diagnosis. Methods. A retrospective review of 2,929 men diagnosed with prostate cancer was performed. Pathological characteristics were compared across age groups: ≤55, 56-75, and >75 years. Results. The study cohort included 133 patients (4.5%), 2,033 patients (69.5%), and 763 patients (26.0%) in the three age groups, respectively. The median pathological Gleason sums in the three age groups were 8, 7, and 8, respectively. The Gleason sum, primary Gleason score, and second primary Gleason score were significantly different among the three age groups (Z = 12.975, p = 0.002; Z = 9.264, p = 0.010; Z = 6.692, p = 0.035, resp.). The percentages of Gleason pattern 5 tumors for the three age groups were 44.4%, 32.3%, and 36.8%, respectively; they were significantly different (χ(2) = 11.641, p = 0.003). The percentages of tumors with Gleason score grade groups 3-5 for the three age groups were 66.9%, 60.5%, and 66.3%, respectively; they were significantly different (χ(2) = 9.401, p = 0.009). Conclusions. The present study indicated that men aged ≤55 years or >75 years show higher levels of clinically significant prostate cancer compared to patients between the ages of 55 and 75 years. Younger and more elderly male patients are more likely to have a more aggressive disease.
PMID
Related Publications

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.

Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.

Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title biomed research international
Publication Year Start




PMID- 28265568
OWN - NLM
STAT- MEDLINE
DA  - 20170307
DCOM- 20170309
LR  - 20170309
IS  - 2314-6141 (Electronic)
VI  - 2017
DP  - 2017
TI  - Are the Pathological Characteristics of Prostate Cancer More Aggressive or More
      Indolent Depending upon the Patient Age?
PG  - 1438027
LID - 10.1155/2017/1438027 [doi]
AB  - Purpose. To identify pathological characteristics of prostate cancer according to
      patient age at diagnosis. Methods. A retrospective review of 2,929 men diagnosed 
      with prostate cancer was performed. Pathological characteristics were compared
      across age groups: </=55, 56-75, and >75 years. Results. The study cohort
      included 133 patients (4.5%), 2,033 patients (69.5%), and 763 patients (26.0%) in
      the three age groups, respectively. The median pathological Gleason sums in the
      three age groups were 8, 7, and 8, respectively. The Gleason sum, primary Gleason
      score, and second primary Gleason score were significantly different among the
      three age groups (Z = 12.975, p = 0.002; Z = 9.264, p = 0.010; Z = 6.692, p =
      0.035, resp.). The percentages of Gleason pattern 5 tumors for the three age
      groups were 44.4%, 32.3%, and 36.8%, respectively; they were significantly
      different (chi2 = 11.641, p = 0.003). The percentages of tumors with Gleason
      score grade groups 3-5 for the three age groups were 66.9%, 60.5%, and 66.3%,
      respectively; they were significantly different (chi2 = 9.401, p = 0.009).
      Conclusions. The present study indicated that men aged </=55 years or >75 years
      show higher levels of clinically significant prostate cancer compared to patients
      between the ages of 55 and 75 years. Younger and more elderly male patients are
      more likely to have a more aggressive disease.
FAU - Ji, Guangjie
AU  - Ji G
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Huang, Cong
AU  - Huang C
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Song, Gang
AU  - Song G
AUID- ORCID: 0000-0003-2176-5419
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Xiong, Gengyan
AU  - Xiong G
AUID- ORCID: 0000-0003-1385-5297
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Fang, Dong
AU  - Fang D
AD  - Department of Andrology, Peking University First Hospital, Institute of Urology, 
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Wang, He
AU  - Wang H
AD  - Department of Radiology, Peking University First Hospital, Beijing, China.
FAU - Hao, Han
AU  - Hao H
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Cai, Lin
AU  - Cai L
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - He, Qun
AU  - He Q
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - He, Zhisong
AU  - He Z
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
FAU - Zhou, Liqun
AU  - Zhou L
AUID- ORCID: 0000-0003-2795-9038
AD  - Department of Urology, Peking University First Hospital, Institute of Urology,
      Peking University, National Urological Cancer Center of China, Beijing, China.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20170207
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Aged
MH  - Aging/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*pathology/*physiopathology
MH  - Retrospective Studies
PMC - PMC5318620
COI - The authors declare that they have no competing interests.
EDAT- 2017/03/08 06:00
MHDA- 2017/03/10 06:00
CRDT- 2017/03/08 06:00
PHST- 2016/10/29 [received]
PHST- 2017/01/07 [revised]
PHST- 2017/01/12 [accepted]
AID - 10.1155/2017/1438027 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:1438027. doi: 10.1155/2017/1438027. Epub 2017 Feb 7.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>